Social Innovation

Supporting Accurate and Efficient Cancer Diagnosis－Precision Medicine

Related SDGs

Precision Medicine

Supporting Accurate and Efficient Cancer Diagnosis

In June 2019, Konica Minolta began joint R&D on next-generation comprehensive cancer gene panel testing with the University of Tokyo and the National Cancer Center Japan Research Institute. This has launched the company's full-scale participation in the effort to promote cancer genomic medicine in Japan. In July 2022, Konica Minolta received marketing approval from the Ministry of Health, Labour and Welfare for its system for cancer genomic profiling exams.

Group company Ambry Genetics Corporation, a major genetic diagnostic provider in the US, has expanded its genetic diagnostic services for cancer patients by launching the CARE Program, which offers these services to healthy and unaffected individuals. The CARE Program uses medical interviews to identify people with a risk of hereditary cancer, provides counseling and tests, and then uses the results to propose a cancer examination plan tailored to each individual.